Clinical trial
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety…
NCT00486265 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00486265 |
|---|---|
| Title | Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) |
| Official title | A Phase I/II, Open-Label, Multi-Center, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD4877 Administered on Days 1, 2 and 3 in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML) Excluding Promyelocytic Leukemia |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | AZD4877 |
| Enrollment | 47 |
| Start date | Jul 1, 2007 |
| Completion | Jul 1, 2009 |
| First posted | Jun 14, 2007 |
| Last update posted | Dec 21, 2010 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: